Printer Friendly

ATRIX LABORATORIES ANNOUNCES PRELIMINARY RESULTS OF CLINICAL TRIAL FOR PERIODONTAL PRODUCT

 FORT COLLINS, Colo., July 28 /PRNewswire/ -- Atrix Laboratories Inc. (NASDAQ: ATRX) announced that the preliminary results from its clarifying trial on its Perio Product appear encouraging. Atrix is developing its Perio Product for the treatment of adult periodontitis.
 Atrix's Perio Product is based on its ATRIGEL(TM) Drug Delivery System, a unique, patented, biodegradable polymeric system. The polymer is placed in liquid form directly into the diseased periodontal pocket where it hardens to form a solid implant.
 John E. Urheim, chief executive officer and Dr. G. Lee Southard, president and chief scientific officer, jointly stated, "Although these are preliminary results from an ongoing study expected to be completed by the end of 1993, we are encouraged by what we have seen so far. We believe we have sufficient data to meet with the FDA in order to confirm our plans of moving ahead with the final phase of testing for this product."
 Atrix Laboratories is a drug delivery company with a unique, patented biodegradable polymeric system that can be used for a broad range of applications including drug delivery, medical devices and the treatment of periodontal disease.
 -0- 7/28/93
 /CONTACT: Susan Sherman of Atrix Laboratories, 303-482-5868/
 (ATRX)


CO: Atrix Laboratories Inc. ST: Colorado IN: MTC SU: PDT

MC -- DV001 -- 6696 07/28/93 10:09 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 28, 1993
Words:218
Previous Article:GMAC REPORTS IMPROVED SECOND QUARTER RESULTS
Next Article:TODHUNTER REPORTS RESULTS FOR THE QUARTER AND NINE MONTHS ENDED JUNE 30, 1993
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters